Magle Chemoswed Holding AB (SE:MAGLE)
:MAGLE
Want to see SE:MAGLE full AI Analyst Report?
Top Page
Magle Chemoswed Holding AB
(MAGLE)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr1.00
▼(-94.19% Downside)
Action:Upgraded
Date:06/17/26
The score is driven primarily by weakening financial performance (recent revenue contraction, large losses, and sustained negative operating/free cash flow) and a strongly bearish technical setup (price well below major moving averages and negative MACD). Valuation provides limited support due to losses (negative P/E) and no dividend yield data.
Positive Factors
Diversified CDMO services and manufacturing revenue
Magle's dual model of contract development services plus contract manufacturing creates diversified, fee‑based revenue typical of CDMO firms. This structure generates repeatable project revenue, creates client lock‑in through technical know‑how, and supports resilience across several quarters as projects ramp and renew.
Negative Factors
Recent sharp revenue decline and operating losses
The reversal from prior growth to TTM revenue contraction and sizable operating losses signals structural demand or execution problems. Persistent operating losses undermine the company's ability to scale fixed‑cost intensive pharma operations, reduce reinvestment capacity, and increase the need for external funding across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified CDMO services and manufacturing revenue
Magle's dual model of contract development services plus contract manufacturing creates diversified, fee‑based revenue typical of CDMO firms. This structure generates repeatable project revenue, creates client lock‑in through technical know‑how, and supports resilience across several quarters as projects ramp and renew.
Read all positive factors
Magle Chemoswed Holding AB (MAGLE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr30.26M
Dividend YieldN/A
Average Volume (3M)1.06K
Price to Earnings (P/E)―
Beta (1Y)0.29
Revenue Growth-3.23%
EPS Growth-1194.44%
CountrySE
Employees147
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.76
Shares Outstanding30,263,191
10 Day Avg. Volume1,291
30 Day Avg. Volume1,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.4
Revenue Forecast (FY)kr377.00M
Magle Chemoswed Holding AB Business Overview & Revenue Model
Company Description
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process develo...
How the Company Makes Money
Magle Chemoswed Holding AB (MAGLE) makes money primarily by providing services and products within pharmaceutical development and manufacturing. Key revenue streams include (1) contract development work (e.g., formulation/process development and r...
Magle Chemoswed Holding AB Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
44
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 270.17M | 282.92M | 236.04M | 170.44M | 145.68M | 132.15M |
| Gross Profit | 219.19M | 232.43M | 221.55M | 152.87M | 134.38M | 110.83M |
| EBITDA | -47.37M | -24.25M | 59.21M | 31.40M | 25.77M | 18.14M |
| Net Income | -180.72M | -159.88M | 11.94M | 12.17M | 9.14M | 4.28M |
Balance Sheet | ||||||
| Total Assets | 823.73M | 911.03M | 1.09B | 272.97M | 252.86M | 237.18M |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 13.59M | 2.72M | 7.08M | 9.88M | 3.98M |
| Total Debt | 356.15M | 346.19M | 359.92M | 60.30M | 50.34M | 36.46M |
| Total Liabilities | 543.97M | 515.19M | 531.58M | 114.75M | 106.09M | 98.39M |
| Stockholders Equity | 279.76M | 395.84M | 560.60M | 158.22M | 146.77M | 138.79M |
Cash Flow | ||||||
| Free Cash Flow | -76.23M | -44.52M | -27.85M | 209.00K | -4.41M | 14.21M |
| Operating Cash Flow | -76.23M | -31.93M | -11.70M | 15.33M | 12.47M | 26.04M |
| Investing Cash Flow | -5.55M | -12.59M | -9.97M | -20.41M | -21.49M | -34.05M |
| Financing Cash Flow | 75.91M | 55.45M | 17.09M | 2.52M | 14.80M | 5.87M |
Magle Chemoswed Holding AB Technical Analysis
Negative
17.20
Price Trends
3.62
Negative
6.10
Negative
12.40
Negative
Market Momentum
-0.85
Positive
19.86
Positive
7.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MAGLE, the sentiment is Negative. The current price of 17.2 is above the 20-day moving average (MA) of 2.62, above the 50-day MA of 3.62, and above the 200-day MA of 12.40, indicating a bearish trend. The MACD of -0.85 indicates Positive momentum. The RSI at 19.86 is Positive, neither overbought nor oversold. The STOCH value of 7.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MAGLE.
Magle Chemoswed Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr463.86M | -32.15 | ― | ― | 22.18% | 48.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr212.24M | 2.00 | -16.90% | ― | -72.49% | ― | |
49 Neutral | kr385.77M | -3.73 | -16.51% | ― | ― | 22.09% | |
48 Neutral | kr443.06M | -4.96 | -25.80% | ― | 35.23% | 64.44% | |
48 Neutral | kr31.30M | -0.39 | -186.13% | ― | ― | 57.42% | |
41 Neutral | kr30.26M | -0.11 | -4.90% | ― | -3.23% | -1194.44% |
* Healthcare Sector Average
SE:MAGLE
Magle Chemoswed Holding AB
1.00
-26.00
-96.30%
SE:XBRANE
Xbrane Biopharma AB
10.30
-19.02
-64.88%
SE:IVACC
Intervacc AB
1.30
0.32
32.79%
SE:GUARD
Guard Therapeutics International AB
1.55
-16.20
-91.26%
SE:IMMU
Immunicum AB
6.30
-0.02
-0.32%
SE:CLBIO
Corline Biomedical AB
17.75
7.75
77.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.